Literature DB >> 25774237

Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy.

Taegyu Park1, Sinae Lee1, Soyeon Park1, Eunsub Lee1, Kisoo Pahk2, Seunghong Rhee2, Jaehyuk Cho2, Chulhan Kim3, Jae Seon Eo1, Jae Gol Choe2, Sungeun Kim2.   

Abstract

PURPOSE: Ovarian cancer is a leading cause of gynecologic malignancy. As symptoms of ovarian cancer are nonspecific, only 20 % of ovarian cancers are diagnosed while they are still limited to the ovaries. Thus, early and accurate detection of disease is important for an improved prognosis. For the accurate and effective diagnosis of ovarian malignancy on (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT), we analyzed several parameters, including visual assessment.
METHOD: A total of 51 peritoneal lesions in 19 patients who showed ovarian masses with diffuse peritoneal infiltration were enrolled. Twelve patients were confirmed to have ovarian malignancy and seven patients with benign disease by pathologic examination. All patients were examined by (18)F-FDG PET/CT, and an additional 2-h delayed (18)F-FDG PET/CT was also performed for 15 patients with 42 peritoneal lesions. We measured semiquantitative parameters including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on a 1-h initial (18)F-FDG PET/CT image (Parameter1) and on a 2-h delayed image (Parameter2). Additionally, retention indices of each parameter were calculated, and each parameter among the malignant and benign lesions was compared by Mann-Whitney U test. We also assessed the visual characteristics of each peritoneal lesion, including metabolic extent, intensity, shape, heterogeneity, and total visual score. Associations between visual grades and malignancy were analyzed using linear by linear association methods. Moreover, a receiver operating characteristic (ROC) curve was analyzed to compare the effectiveness of significant parameters. RESULT: In a comparison between the malignant and benign groups in the analysis of 51 total peritoneal lesions, SUVmax1, SUVmean1, and TLG1 showed significant differences. Also, in the analysis of 42 peritoneal lesions that underwent an additional 2-h (18)F-FDG PET/CT examination, SUVmax1,2, SUVmean1,2, TLG2, and the RI of TLG showed significant differences between the malignant and benign groups. MTV did not show significant differences in either the analysis of 51 peritoneal lesions or of 42 lesions. Regarding visual assessments, metabolic intensity, shape, heterogeneity, and total visual score showed an association with malignancy. In the ROC analysis, the AUC of the visual score was larger than the AUC of other parameters in both the analyses of 51 peritoneal lesions and of 42 lesions.
CONCLUSION: Although further study with a larger patient population is needed, the visual assessment of (18)F-FDG PET/CT imaging has a primary role in the detection of malignancy in ovarian cancer patients with assistance from other semi-quantitative parameters.

Entities:  

Keywords:  18F-FDG PET/CT; Diagnostic value; Maximal standardized uptake value; Metabolic tumor volume; Ovarian cancer; Total lesion glycolysis; Visual assessment

Year:  2014        PMID: 25774237      PMCID: PMC4354788          DOI: 10.1007/s13139-014-0303-3

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  30 in total

1.  Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer.

Authors:  Tom R Miller; Edward Pinkus; Farrokh Dehdashti; Perry W Grigsby
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

2.  The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.

Authors:  Signe Risum; Claus Høgdall; Annika Loft; Anne K Berthelsen; Estrid Høgdall; Lotte Nedergaard; Lene Lundvall; Svend A Engelholm
Journal:  Gynecol Oncol       Date:  2007-01-16       Impact factor: 5.482

3.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

Review 4.  Role of PET/CT in ovarian cancer.

Authors:  Priyanka Prakash; Carmel G Cronin; Michael A Blake
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

5.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.

Authors:  R Hustinx; R J Smith; F Benard; D I Rosenthal; M Machtay; L A Farber; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-10

6.  Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.

Authors:  Mathieu Hatt; Dimitris Visvikis; Nidal M Albarghach; Florent Tixier; Olivier Pradier; Catherine Cheze-le Rest
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-02       Impact factor: 9.236

Review 7.  Clinical role of FDG PET in evaluation of cancer patients.

Authors:  Lale Kostakoglu; Harry Agress; Stanley J Goldsmith
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

8.  Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.

Authors:  Danny L Costantini; Reza Vali; Jeffery Chan; Susan McQuattie; Martin Charron
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

9.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.

Authors:  Hedva Lerman; Ur Metser; Dan Grisaru; Ami Fishman; Gennady Lievshitz; Einat Even-Sapir
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

10.  18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.

Authors:  Colleen M Costelloe; Homer A Macapinlac; John E Madewell; Nancy E Fitzgerald; Osama R Mawlawi; Eric M Rohren; A Kevin Raymond; Valerae O Lewis; Peter M Anderson; Roland L Bassett; Robyn K Harrell; Edith M Marom
Journal:  J Nucl Med       Date:  2009-03       Impact factor: 10.057

View more
  4 in total

1.  Quantitative single-photon emission computed tomography/computed tomography for technetium pertechnetate thyroid uptake measurement.

Authors:  Hyunjong Lee; Ji Hyun Kim; Yeon-Koo Kang; Jae Hoon Moon; Young So; Won Woo Lee
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 2.  Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed?

Authors:  Subapriya Suppiah; Wing Liong Chang; Hasyma Abu Hassan; Chalermrat Kaewput; Andi Anggeriana Andi Asri; Fathinul Fikri Ahmad Saad; Abdul Jalil Nordin; Sobhan Vinjamuri
Journal:  World J Nucl Med       Date:  2017 Jul-Sep

Review 3.  A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies.

Authors:  Nasim Vahidfar; Saeed Farzanefar; Hojjat Ahmadzadehfar; Eóin N Molloy; Elisabeth Eppard
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

4.  Repurposing 11C-PS13 for PET Imaging of Cyclooxygenase-1 in Ovarian Cancer Xenograft Mouse Models.

Authors:  Amanda J Boyle; Junchao Tong; Sami S Zoghbi; Victor W Pike; Robert B Innis; Neil Vasdev
Journal:  J Nucl Med       Date:  2020-09-25       Impact factor: 10.057

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.